188.41 USD
+95.64 (+103.09%)
At close: Feb 2, 2026
189.62 USD
+1.21 (+0.64%)
Pre-Market: 2/3/2026, 4:04:30 AM
We assign a fundamental rating of 6 out of 10 to AZN. AZN was compared to 191 industry peers in the Pharmaceuticals industry. While AZN has a great profitability rating, there are some minor concerns on its financial health. AZN has a correct valuation and a medium growth rate. AZN also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- AZN had positive earnings in the past year.
- In the past year AZN had a positive cash flow from operations.
- AZN had positive earnings in each of the past 5 years.
- In the past 5 years AZN always reported a positive cash flow from operatings.
1.2 Ratios
- AZN has a Return On Assets of 8.21%. This is amongst the best in the industry. AZN outperforms 89.53% of its industry peers.
- AZN has a Return On Equity of 20.48%. This is amongst the best in the industry. AZN outperforms 90.58% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 14.42%, AZN belongs to the top of the industry, outperforming 94.24% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for AZN is in line with the industry average of 12.82%.
- The last Return On Invested Capital (14.42%) for AZN is above the 3 year average (11.62%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
- AZN's Profit Margin of 16.17% is amongst the best of the industry. AZN outperforms 88.48% of its industry peers.
- In the last couple of years the Profit Margin of AZN has grown nicely.
- AZN's Operating Margin of 24.34% is amongst the best of the industry. AZN outperforms 91.10% of its industry peers.
- AZN's Operating Margin has improved in the last couple of years.
- The Gross Margin of AZN (81.90%) is better than 85.34% of its industry peers.
- In the last couple of years the Gross Margin of AZN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AZN is still creating some value.
- Compared to 1 year ago, AZN has about the same amount of shares outstanding.
- Compared to 5 years ago, AZN has more shares outstanding
- AZN has a worse debt/assets ratio than last year.
2.2 Solvency
- AZN has an Altman-Z score of 6.11. This indicates that AZN is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 6.11, AZN is in the better half of the industry, outperforming 77.49% of the companies in the same industry.
- The Debt to FCF ratio of AZN is 3.41, which is a good value as it means it would take AZN, 3.41 years of fcf income to pay off all of its debts.
- AZN has a Debt to FCF ratio of 3.41. This is amongst the best in the industry. AZN outperforms 87.43% of its industry peers.
- A Debt/Equity ratio of 0.61 indicates that AZN is somewhat dependend on debt financing.
- AZN's Debt to Equity ratio of 0.61 is on the low side compared to the rest of the industry. AZN is outperformed by 68.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 6.11 |
ROIC/WACC1.59
WACC9.06%
2.3 Liquidity
- AZN has a Current Ratio of 0.88. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
- AZN has a worse Current ratio (0.88) than 87.43% of its industry peers.
- A Quick Ratio of 0.69 indicates that AZN may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.69, AZN is doing worse than 85.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
- AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
- Measured over the past years, AZN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.59% on average per year.
- Looking at the last year, AZN shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
- Measured over the past years, AZN shows a quite strong growth in Revenue. The Revenue has been growing by 17.27% on average per year.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
- Based on estimates for the next years, AZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.37% on average per year.
- AZN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.20% yearly.
EPS Next Y14.52%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
EPS Next 5Y12.37%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 40.96 indicates a quite expensive valuation of AZN.
- 77.49% of the companies in the same industry are more expensive than AZN, based on the Price/Earnings ratio.
- AZN is valuated rather expensively when we compare the Price/Earnings ratio to 28.41, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 35.43 indicates a quite expensive valuation of AZN.
- 71.20% of the companies in the same industry are more expensive than AZN, based on the Price/Forward Earnings ratio.
- AZN is valuated rather expensively when we compare the Price/Forward Earnings ratio to 25.64, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.96 | ||
| Fwd PE | 35.43 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, AZN is valued cheaply inside the industry as 80.10% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, AZN is valued a bit cheaper than 77.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.06 | ||
| EV/EBITDA | 29.3 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- AZN has an outstanding profitability rating, which may justify a higher PE ratio.
- AZN's earnings are expected to grow with 12.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.82
PEG (5Y)2.2
EPS Next 2Y13.43%
EPS Next 3Y12.85%
5. Dividend
5.1 Amount
- AZN has a Yearly Dividend Yield of 1.82%.
- Compared to an average industry Dividend Yield of 0.62, AZN pays a better dividend. On top of this AZN pays more dividend than 91.62% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.83, AZN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.82% |
5.2 History
- The dividend of AZN has a limited annual growth rate of 1.40%.
- AZN has been paying a dividend for at least 10 years, so it has a reliable track record.
- AZN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
5.3 Sustainability
- AZN pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
- The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
188.41
+95.64 (+103.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-10 2026-02-10/amc
Inst Owners49.17%
Inst Owner Change0.27%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap584.18B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target97.79 (-48.1%)
Short Float %0.37%
Short Ratio1.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.82% |
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years1
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)0.46%
PT rev (3m)6.81%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)0.48%
EPS NY rev (1m)2.29%
EPS NY rev (3m)0.81%
Revenue NQ rev (1m)0.18%
Revenue NQ rev (3m)0.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.96 | ||
| Fwd PE | 35.43 | ||
| P/S | 10.05 | ||
| P/FCF | 61.06 | ||
| P/OCF | 38.59 | ||
| P/B | 12.73 | ||
| P/tB | N/A | ||
| EV/EBITDA | 29.3 |
EPS(TTM)4.6
EY2.44%
EPS(NY)5.32
Fwd EY2.82%
FCF(TTM)3.09
FCFY1.64%
OCF(TTM)4.88
OCFY2.59%
SpS18.75
BVpS14.8
TBVpS-4.36
PEG (NY)2.82
PEG (5Y)2.2
Graham Number39.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 6.11 |
F-Score7
WACC9.06%
ROIC/WACC1.59
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y14.52%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
EPS Next 5Y12.37%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.82%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
What is the valuation status for AZN stock?
ChartMill assigns a valuation rating of 5 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.
How profitable is ASTRAZENECA PLC-SPONS ADR (AZN) stock?
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for AZN stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 40.96 and the Price/Book (PB) ratio is 12.73.
What is the expected EPS growth for ASTRAZENECA PLC-SPONS ADR (AZN) stock?
The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 14.52% in the next year.